Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype-genotype study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Characteristics of white blood cell count in acute lymphoblastic leukemia : A COST LEGEND phenotype-genotype study. / Helenius, Marianne; Vaitkeviciene, Goda; Abrahamsson, Jonas; Jonsson, Ólafur Gisli; Lund, Bendik; Harila-Saari, Arja; Vettenranta, Kim; Mikkel, Sirje; Stanulla, Martin; Lopez-Lopez, Elixabet; Waanders, Esmé; Madsen, Hans O; Marquart, Hanne Vibeke; Modvig, Signe; Gupta, Ramneek; Schmiegelow, Kjeld; Nielsen, Rikke Linnemann.

I: Pediatric Blood and Cancer, Bind 69, Nr. 6, 2022, s. e29582.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Helenius, M, Vaitkeviciene, G, Abrahamsson, J, Jonsson, ÓG, Lund, B, Harila-Saari, A, Vettenranta, K, Mikkel, S, Stanulla, M, Lopez-Lopez, E, Waanders, E, Madsen, HO, Marquart, HV, Modvig, S, Gupta, R, Schmiegelow, K & Nielsen, RL 2022, 'Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype-genotype study', Pediatric Blood and Cancer, bind 69, nr. 6, s. e29582. https://doi.org/10.1002/pbc.29582

APA

Helenius, M., Vaitkeviciene, G., Abrahamsson, J., Jonsson, Ó. G., Lund, B., Harila-Saari, A., Vettenranta, K., Mikkel, S., Stanulla, M., Lopez-Lopez, E., Waanders, E., Madsen, H. O., Marquart, H. V., Modvig, S., Gupta, R., Schmiegelow, K., & Nielsen, R. L. (2022). Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype-genotype study. Pediatric Blood and Cancer, 69(6), e29582. https://doi.org/10.1002/pbc.29582

Vancouver

Helenius M, Vaitkeviciene G, Abrahamsson J, Jonsson ÓG, Lund B, Harila-Saari A o.a. Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype-genotype study. Pediatric Blood and Cancer. 2022;69(6):e29582. https://doi.org/10.1002/pbc.29582

Author

Helenius, Marianne ; Vaitkeviciene, Goda ; Abrahamsson, Jonas ; Jonsson, Ólafur Gisli ; Lund, Bendik ; Harila-Saari, Arja ; Vettenranta, Kim ; Mikkel, Sirje ; Stanulla, Martin ; Lopez-Lopez, Elixabet ; Waanders, Esmé ; Madsen, Hans O ; Marquart, Hanne Vibeke ; Modvig, Signe ; Gupta, Ramneek ; Schmiegelow, Kjeld ; Nielsen, Rikke Linnemann. / Characteristics of white blood cell count in acute lymphoblastic leukemia : A COST LEGEND phenotype-genotype study. I: Pediatric Blood and Cancer. 2022 ; Bind 69, Nr. 6. s. e29582.

Bibtex

@article{dc99283b001341d5854d2ec189c28981,
title = "Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype-genotype study",
abstract = "BACKGROUND: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well-known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood.METHODS: We included patients treated with the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-2008 protocol (N = 2347, 72% were genotyped by Illumina Omni2.5exome-8-Bead chip) aged 1-45 years, diagnosed with B-cell precursor (BCP-) or T-cell ALL (T-ALL) to investigate the variation in WBC. Spline functions of WBC were fitted correcting for association with age across ALL subgroups of immunophenotypes and karyotypes. The residuals between spline WBC and actual WBC were used to identify WBC-associated germline genetic variants in a genome-wide association study (GWAS) while adjusting for age and ALL subtype associations.RESULTS: We observed an overall inverse correlation between age and WBC, which was stronger for the selected patient subgroups of immunophenotype and karyotypes (ρBCP-ALL = -.17, ρT-ALL = -.19; p < 3 × 10-4 ). Spline functions fitted to age, immunophenotype, and karyotype explained WBC variation better than age alone (ρ = .43, p << 2 × 10-6 ). However, when the spline-adjusted WBC residuals were used as phenotype, no GWAS significant associations were found. Based on available annotation, the top 50 genetic variants suggested effects on signal transduction, translation initiation, cell development, and proliferation.CONCLUSION: These results indicate that host genome variants do not strongly influence WBC across ALL subsets, and future studies of why some patients are more prone to hyperleukocytosis should be performed within specific ALL subsets that apply more complex analyses to capture potential germline variant interactions and impact on WBC.",
keywords = "Genome-Wide Association Study, Genotype, Humans, Leukocyte Count, Phenotype, Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Prognosis",
author = "Marianne Helenius and Goda Vaitkeviciene and Jonas Abrahamsson and Jonsson, {{\'O}lafur Gisli} and Bendik Lund and Arja Harila-Saari and Kim Vettenranta and Sirje Mikkel and Martin Stanulla and Elixabet Lopez-Lopez and Esm{\'e} Waanders and Madsen, {Hans O} and Marquart, {Hanne Vibeke} and Signe Modvig and Ramneek Gupta and Kjeld Schmiegelow and Nielsen, {Rikke Linnemann}",
note = "{\textcopyright} 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.",
year = "2022",
doi = "10.1002/pbc.29582",
language = "English",
volume = "69",
pages = "e29582",
journal = "Medical and Pediatric Oncology. Supplement",
issn = "0740-8226",
publisher = "JohnWiley & Sons, Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Characteristics of white blood cell count in acute lymphoblastic leukemia

T2 - A COST LEGEND phenotype-genotype study

AU - Helenius, Marianne

AU - Vaitkeviciene, Goda

AU - Abrahamsson, Jonas

AU - Jonsson, Ólafur Gisli

AU - Lund, Bendik

AU - Harila-Saari, Arja

AU - Vettenranta, Kim

AU - Mikkel, Sirje

AU - Stanulla, Martin

AU - Lopez-Lopez, Elixabet

AU - Waanders, Esmé

AU - Madsen, Hans O

AU - Marquart, Hanne Vibeke

AU - Modvig, Signe

AU - Gupta, Ramneek

AU - Schmiegelow, Kjeld

AU - Nielsen, Rikke Linnemann

N1 - © 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well-known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood.METHODS: We included patients treated with the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-2008 protocol (N = 2347, 72% were genotyped by Illumina Omni2.5exome-8-Bead chip) aged 1-45 years, diagnosed with B-cell precursor (BCP-) or T-cell ALL (T-ALL) to investigate the variation in WBC. Spline functions of WBC were fitted correcting for association with age across ALL subgroups of immunophenotypes and karyotypes. The residuals between spline WBC and actual WBC were used to identify WBC-associated germline genetic variants in a genome-wide association study (GWAS) while adjusting for age and ALL subtype associations.RESULTS: We observed an overall inverse correlation between age and WBC, which was stronger for the selected patient subgroups of immunophenotype and karyotypes (ρBCP-ALL = -.17, ρT-ALL = -.19; p < 3 × 10-4 ). Spline functions fitted to age, immunophenotype, and karyotype explained WBC variation better than age alone (ρ = .43, p << 2 × 10-6 ). However, when the spline-adjusted WBC residuals were used as phenotype, no GWAS significant associations were found. Based on available annotation, the top 50 genetic variants suggested effects on signal transduction, translation initiation, cell development, and proliferation.CONCLUSION: These results indicate that host genome variants do not strongly influence WBC across ALL subsets, and future studies of why some patients are more prone to hyperleukocytosis should be performed within specific ALL subsets that apply more complex analyses to capture potential germline variant interactions and impact on WBC.

AB - BACKGROUND: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well-known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood.METHODS: We included patients treated with the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-2008 protocol (N = 2347, 72% were genotyped by Illumina Omni2.5exome-8-Bead chip) aged 1-45 years, diagnosed with B-cell precursor (BCP-) or T-cell ALL (T-ALL) to investigate the variation in WBC. Spline functions of WBC were fitted correcting for association with age across ALL subgroups of immunophenotypes and karyotypes. The residuals between spline WBC and actual WBC were used to identify WBC-associated germline genetic variants in a genome-wide association study (GWAS) while adjusting for age and ALL subtype associations.RESULTS: We observed an overall inverse correlation between age and WBC, which was stronger for the selected patient subgroups of immunophenotype and karyotypes (ρBCP-ALL = -.17, ρT-ALL = -.19; p < 3 × 10-4 ). Spline functions fitted to age, immunophenotype, and karyotype explained WBC variation better than age alone (ρ = .43, p << 2 × 10-6 ). However, when the spline-adjusted WBC residuals were used as phenotype, no GWAS significant associations were found. Based on available annotation, the top 50 genetic variants suggested effects on signal transduction, translation initiation, cell development, and proliferation.CONCLUSION: These results indicate that host genome variants do not strongly influence WBC across ALL subsets, and future studies of why some patients are more prone to hyperleukocytosis should be performed within specific ALL subsets that apply more complex analyses to capture potential germline variant interactions and impact on WBC.

KW - Genome-Wide Association Study

KW - Genotype

KW - Humans

KW - Leukocyte Count

KW - Phenotype

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics

KW - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

KW - Prognosis

U2 - 10.1002/pbc.29582

DO - 10.1002/pbc.29582

M3 - Journal article

C2 - 35316565

VL - 69

SP - e29582

JO - Medical and Pediatric Oncology. Supplement

JF - Medical and Pediatric Oncology. Supplement

SN - 0740-8226

IS - 6

ER -

ID: 307911527